The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.

FDA’s Peter Marks says educating academics about CMC would help them understand why it is necessary to do things in a standardized way. He predicts the field will move away from individual manufacturing platforms in the next five to 10 years.

Daily notebook from the J.P. Morgan Healthcare Conference:  Roche expects continued high interest in partnering; Vir explains cost-cutting gives it a stronger base; bluebird provides Lyfgenia performance to date; Sage details Zurzuvae launch trajectory; and Madrigal lays out next steps in NASH. 

An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.